ABCB6 and diffuse large B-cell lymphoma: To analyze whether the transcriptional program induced by miR-28+ibrutinib combination therapy correlates with cell proliferation blockade, we first performed a pulsed BrdU and cell cycle analysis 20 h after ibrutinib treatment in miR-28–transduced MD-901 ABC-DLBCL and SUDHL4 GCB-DLBCL cells.